Skip to content

Study · Randomized controlled trial · n = 114 · 2025

2 results

The impact of semaglutide on liver fat assessed by serial cardiac CT scans in patients with type 2 diabetes: Results from STOP trial.

Golub IS, Manubolu VS, Aldana-Bitar J, Dahal S, Verghese D, Alalawi L, Krishnan S, Kianoush S, Benzing T, Ichikawa K, Kinninger A, Fazlalizadeh H and 9 more

Show all authors

Pourafkari L, Ahmad K, Susarla S, Mangaoang C, Ghanem AK, Javier DA, Hamal S, Roy SK, Budoff MJ

Nutrition, metabolism, and cardiovascular diseases : NMCD5 Apr 2025Cited by 10 (Europe PMC)

PMID40287313 (opens in a new tab)DOI10.1016/j.numecd.2025.104036 (opens in a new tab)PepBankPUB-40287313
Publisher pagePubMedAsk about this study
Jump to 2 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study2

2 results from studies that gave the peptide. 2 results from people.

  1. 01HumanRandomized controlled trialEfficacy outcome

    In adults with type 2 diabetes, liver attenuation improved by 1.4 HU with semaglutide and worsened by 1.9 HU with placebo over 12 months.

    In plain wordsIn adults with type 2 diabetes, liver fat on CT scans improved with semaglutide and worsened with placebo over 12 months.

    Peptide
    Semaglutide
    Outcome
    DecreaseLiver fat by CT attenuation, average change over 12 months
    Study

    n = 114

    Comparator
    Placebo
    Analysis
    Secondary
    Outcome group
    Liver fat and liver function · Liver
    Studied dose
    Dose not stated · 12 monthsAs given in this study (human).

    Measurements

    Liver attenuation change
    1.4 HU
    semaglutide
    Liver attenuation change
    −1.9 HU
    placebo

    Source sentences

    Summary
    The average of three liver measures over 12 months showed an improvement in the semaglutide group of 1.4 ± 9.0 mean HU, versus a worsening in the placebo group of 1.9 ± 9.5 mean HU.
    2 context sentences
    Summary · context
    STOP is a randomized controlled trial that evaluated the semaglutide treatment effect on coronary atherosclerosis progression (STOP) in type 2 diabetes.
    Summary · context
    59 participants were in the semaglutide group and 55 were in the placebo group, and these subjects were followed for 12 months.
  2. 02HumanRandomized controlled trialEfficacy outcome

    In adults with type 2 diabetes, after multivariable adjustment, liver attenuation improved by 4.4 HU more with semaglutide than with placebo (p = 0.002).

    In plain wordsIn adults with type 2 diabetes, semaglutide improved liver fat on CT scans more than placebo after adjusting for other factors.

    Peptide
    Semaglutide
    Outcome
    DecreaseLiver fat by CT attenuation, adjusted difference
    Study

    n = 114

    Comparator
    Placebo
    Analysis
    Secondary
    Outcome group
    Liver fat and liver function · Liver
    Studied dose
    Dose not stated · 12 monthsAs given in this study (human).

    Measurements

    Adjusted difference in liver attenuation
    4.4 HU
    semaglutide vs placebo

    Source sentences

    Summary
    The multivariable linear regression models (after adjusting for age, gender, BMI, hypertension, hyperlipidemia, past smoking and baseline liver attenuation) showed that average liver attenuation measures improved by 4.4 HU in the semaglutide group when compared to the placebo group (p = 0.002).
    2 context sentences
    Summary · context
    STOP is a randomized controlled trial that evaluated the semaglutide treatment effect on coronary atherosclerosis progression (STOP) in type 2 diabetes.
    Summary · context
    59 participants were in the semaglutide group and 55 were in the placebo group, and these subjects were followed for 12 months.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    11 Oct 2026, 00:04 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 03:06 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.